Chronic obstructive pulmonary disease in the elderly: An update on pharmacological management

Drugs and Aging

Volumn 26, Issue 6, 2009, Pages 447-456

  Dzierba, Amy L ^a   Jelic, Sanja ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b PH8 Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CORTICOSTEROID; FLUTICASONE PROPIONATE; FORMOTEROL; IPRATROPIUM BROMIDE; MACROLIDE; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

AGED; AGING; BRONCHODILATATION; BRONCHODILATING ACTIVITY; CARDIOVASCULAR DISEASE; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSED ANGLE GLAUCOMA; COMORBIDITY; CORTICOSTEROID THERAPY; COUGHING; DEATH; DISEASE EXACERBATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG WITHDRAWAL; GERIATRIC CARE; HEADACHE; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HEART PALPITATION; HUMAN; LEG CRAMP; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; OSTEOPOROSIS; PNEUMONIA; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINUS TACHYCARDIA; STROKE; TREMOR; URINE RETENTION; VOMITING; XEROSTOMIA;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AGED; BRONCHODILATOR AGENTS; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; XANTHINES;

EID: 67749116608     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-200926060-00001     Document Type: Review

References (94)

1. National Center for Health Statistics. Report of final mortality statistics, 2005 [online]. Available from URL: http://www.cdc.gov/nchs/data/ nvsr/nvsr56/nvsr56-10.pdf [Accessed 2008 Apr 20]
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2007 [online]. Available from URL: http://www.goldcopd.org [Accessed 2008 Apr 20]
3. National Center for Health Statistics. Report of final mortality statistics, 2005 [online]. Available from URL http://www.cdc.gov/nchs/data/ series/sr-10/sr10-235.pdf [Accessed 2008 Apr 20]
4. Silverman EK, Weiss ST, Drazen JM, et al. Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 2152-58
5. Wise RA. Changing smoking patterns and mortality from chronic obstructive pulmonary disease. Prev Med 1997; 26: 418-21
6. Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstructive pulmonary disease. Arch Intern Med 2000; 160: 2653-8
7. Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. BMJ 2003; 326: 196
8. Maciejewski ML, Perkins M, Li YF, et al. Utilization and expenditures of veterans obtaining primary care in com- munity clinics and VA medical centers: an observational cohort study. BMC Health Serv Res 2007; 7: 56
9. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998; 80: 437-41
10. Akazawa M, Stearns SC, Biddle AK. Assessing treatment effects of inhaled corticosteroids on medical expenses and exacerbations among COPD patients: longitudinal analysis of managed care claims. Health Serv Res 2008; 29: 1-19
11. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: American Thoracic Society. Am J Respir Crit Care Med 1995; 152: S77-121
12. O'Donnell DE, Aaron S, Bourbeau J, et al. Thoracic Society recommendation for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007; 14: S5B-32B
13. World Health Organization. Definition of an older or elderly person [online]. Available from URL: http://www.who.int/healthinfo/survey/ ageingdefnolder/en/ [Accessed 2008 Oct 18]
14. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-9
15. Guyatt GH, Townsend M, Pugsley SO, et al. Bronchodilators in acute airflow limitation: effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987; 135: 1069-74
16. Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 526-34
17. Holt TB. Inhaled beta agonists. Respir Care 2007; 52: 820-32 18. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-69
18. Hanania NA, Sharafkhaneh A, Barber R, et al. β-Agonist intrinsic efficacy. Am J Respir Crit Care Med 2002; 165: 1353-8
19. Johnson M. The β-adrenoceptor. Am J Respir Crit Care Med 1998; 158: S146-53
20. Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the assessment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815-21
21. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3 month trial. Eur Respir J 2002; 19: 936-43
22. Rennard SI, Anderson W, ZuWallack R, et al. Use of a longacting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive disease. Am J Respir Crit Care Med 2001; 163: 1087-92
23. Mahler DA, Donuhue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 956-65
24. Stockley RA, Whitehead PJ, Williams MK. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis. Respir Res 2006; 7: 147
25. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting β-agonists in stable COPD. Chest 2008; 133: 1079-87
26. United States Food and Drug Administration. FDA Public Health Advisory: Serevent Diskus, Advir Diskus and For- adil [online]. Available from URL: http://www.fda.gov/ CDER/Drug/advisory/LABA.htm [Accessed 2008 Apr 20]
27. Nelson HS, Weiss ST, Bleecker ER, et al. on behalf of the SMART study group. The Salmeterol Multicenter Asthma Research Trial. Chest 2006; 129: 15-26
28. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J 2004; 24: 822-33
29. Lange P, Parner J, Vestbo J, et al. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194-200
30. Padeletti M, Jelic S, LeJemtel TH. Coexistent chronic obstructive pulmonary disease and heart failure in the elderly. Int J Cardiol 2008; 125: 209-15
31. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD. Chest 2004; 125: 2309-21
32. Au DH, Lamaitre RN, Curtis JR, et al. The risk of myocardial infarction associated with inhaled β-adrenoreceptor agonists. Am J Respir Crit Care Med 2000; 161: 827-30
33. Au DH, Curtis JR, Every NR, et al. Association between inhaled β-agonists and the risk of unstable angina and myocardial infarction. Chest 2002; 121: 846-51
34. GlaxoSmithKline. Ventolin [package insert]. Research Triangle Park (NC): GlaxoSmithKline, 2001
35. Ferguson GT, Funck-Brentano C, Fischer T, et al. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123: 1817-24
36. Tamaoki J, Chiyotani A, Tagaya E, et al. Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax 1994; 49: 545-8
37. Wise RA, Tashkin DP. Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. Am J Med 2007; 120: S4-13
38. van Noord JA, Bantje ThA, Eland ME, et al. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000; 55: 289-94
39. Boehringer Ingelheim Pharmaceuticals. Tiotropium [package insert]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals Inc., 2007
40. Briggs DD, Covelli H, Lapidus R, et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005; 18: 397-404
41. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55
42. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404
43. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-40
44. Rodrigo GJ, Nannini LJ. Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther 2007; 20: 495-502
45. Boehringer Ingelheim Pharmaceuticals. Atrovent [package insert]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals Inc., 2007
46. Pras E, Stienlauf S, Pinkhas J, et al. Urinary retention associated with ipratropium bromide. DICP 1991; 25: 939-40
47. United States Food and Drug Administration. Early communication about ongoing safety review of tiotropium [online]. Available from URL: http://www.fda.gov/CDER/ Drug/early-comm/tiotropium.htm [Accessed 2008 Apr 20]
48. DeLuise C, Lanes SF, Jacobsen J, et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007; 22: 267-72
49. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16: 63-70
50. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. JAMA 2008; 300: 1439-50
51. Viires N, Aubier M, Murciano D, et al. Effects of theophylline on isolated diaphragmatic fibers: a model for pharmacologic studies on diaphragmatic contractility. Am Rev Respir Dis 1986; 133: 1060-4
52. Murciano D, Auclair MH, Pariente R, et al. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320: 1521-5
53. McKay SE, Howie CA, Thomson AH, et al. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993; 48 (3): 227-32
54. Moxham J. Aminophylline and the respiratory muscles: an alternative view. Clin Chest Med 1988; 9: 325-36
55. ZuWallack R, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-70
56. Barr RG, Rowe BH, Camargo CA. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomized trials. BMJ 2003; 327: 6
57. O'Mahony MS, Woodhouse KW. Age environmental and drug metabolism. Pharmacol Ther 1994; 61: 279-87
58. Le Couteur DG, McLean AJ. The aging liver: drug clearance and oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998; 34: 359-73
59. Tanaka E. In vitro age-related changes in hepatic drugoxidizing capacity in humans. J Clin Pharm Ther 1998; 23: 247-55
60. Jackson SH, Johnston A, Woolard R, et al. The relationshipbetween theophylline clearance and age in adult life. Eur J Clin Pharmacol 1989; 36: 29-34
61. COMBIVENT Inhalation Aerosol Study Group. In chronicobstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest 1994; 105: 1411-19
62. Campbell S. For COPD a combination of ipratropiumbromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999; 159: 156-60
63. van Noord JA, Aumann JL, Janssens E, et al. Comparisonof tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214-22
64. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-17
65. Aaron SD, Vandermheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for the treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-55
66. Tashkin DP, Celli B, Senn S, et al. A 4-year trial to tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54
67. O'Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in COPD. Eur Respir J 2004; 24: 86-94
68. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 1995; 127: 809-17
69. ZuWallack RL. The roles of bronchodilators, supplementaloxygen, and ventilatory assistance in the pulmonary re habilitation of patients with chronic obstructive pulmonary disease. Respir Care 2008; 53: 1190-95
70. Calverely PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive disease. N Engl J Med 2007; 356: 775-89
71. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-53
72. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 1999; 353: 1819-23
73. Burge PS, Calverley PM, Jones PW, et al. Randomized, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303
74. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease: Lung Health Study II. N Engl J Med 2000; 343: 1902-9
75. Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007; 131: 682-9
76. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995-2004
77. Spencer S, Calverley PM, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23 (5): 698-702
78. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic pulmonary obstructive disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59-65
79. Gartlehner G, Hanson RA, Carson SS, et al. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006; 4: 253-62
80. van der Valk P, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166 (10): 1358-63
81. Calverley PM, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: randomized controlled trial. Lancet 2003; 361: 449-56
82. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81
83. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-8
84. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-7
85. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144-9
86. Huiart L, Ernst P, Ranouil X, et al. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 25: 634-9
87. Varas-Lorenzo C, Rodriguez LA, Maguire A, et al. Use oforal corticosteroids and the risk of acute myocardial in farction. Atherosclerosis 2007; 192: 376-83
88. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162-6
89. Nazir SA, Al-Hamed MM, Erbland ML. Chronic obstructive pulmonary disease in the older patient. Clin Chest Med 2007; 28: 703-15
90. Chapman KR, Love L, Brubaker H. A comparison of breathactuated and conventional meter-dose inhaler inhalation techniques in elderly subjects. Chest 1993; 104: 1332-7
91. Ho SF, O'Mahoney MS, Steward JA, et al. Inhaler techniquein older people in the community. Age Ageing 2004; 33: 185-8
92. Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderlyCOPD patients: time for re-evaluation? Age Ageing 2007; 36: 213-8
93. Teale C, Jones A, Patterson CT, et al. Community survey ofhome nebulized technique by elderly people. Age Ageing 1995; 24: 276-7
94. Dolovich MB, Ahrens RC, Hess DR, et al. Device selectionand outcomes of aerosol therapy: evidence-based guidelines. Chest 2005; 127: 335-71